







**PAN- CANCER ONE LIQUID BIOPSY TEST** 




Liquid "biopsy" technology enables the molecular interrogation to obtain tumor-derived information from body fluids like blood urine etc. Unlike biopsy, liquid biopsies don't test tumor tissue directly instead they test for evidence of a tumor in the blood sample and therefore liquid biopsies are minimally invasive.

How: Liquid biopsy utilizes circulating tumor DNA (ctDNA): ctDNA is a DNA fragment from the tumor cell circulating in your blood. ctDNA exists as short fragments (150–200 base pairs) and inherits the tumor-specific abnormalities from its tumor origins such as single-nucleotide mutations epigenetics changes and copy number variations. These molecular features are amenable to PCR- and next generation sequencing (NGS)-based analyses and can then be used as specific biomarkers for cancer monitoring and management.

## WHY TEST:

ctDNA profiling is transforming molecular oncology to precision medicine by playing a major a role in cancer diagnosis, prognosis and measuring treatment response.

- Identify actionable somatic mutations/ alterations in tumors without an invasive biopsy
- Test for new actionable alterations
- Determine treatment efficacy
- Assess remission or progression
- Determine presence of disease with no prior evidence





# PAN CANCER ONE LIQUID BIOPSY TEST

Our Oncomine Liquid Biopsy Pan- Cancer NGS Panel is part of a complete solution to detect multiple targets in tumor-derived DNA and RNA isolated from the plasma fraction of whole blood. The 52-gene panel enables detection of SNVs CNVs and gene fusion events all in single test.

## **CANCERS TYPES:**

- Lung
- Bladder
- Brain & CNS
- Breast
- Cervical
- Colorectal

- Endometrial
- Esophageal
- Gastric
- Head & Neck
- Kidney
- Liver

- Melanoma
- Ovarian
- Pancreatic
- **Prostate**
- Sarcoma
- Thyroid

#### **PANEL INFORMATION:**

| Hotspot genes (SNVs) and short indels                | Gene fusions   | Exon skipping           | Copy number genes (CNVs)   | Tumor suppressor genes |
|--|--|-------------------------|--|------------------------|
| CHEK2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ESR1, FGFR1 | FGFR1,FGFR2<br>FGFR3,MET,<br>NTRK1,NTRK, RET<br>ROS1 | MET exon 14<br>skipping | CCND1,CCND2 CCND3,CDK4,<br>CDK6,EGFR, ERBB2,FGFR1,<br>FGFR2,FGFR3, MET MYC | ' '                    |

### WHO CAN BENEFIT FROM THIS TEST:

- · For molecular tumor profiling in patients who may not be able to have a tissue biopsy due to the inaccessibility of their tumors or because they have other health conditions that prevent them from undergoing the invasive procedure.
- Monitoring treatment response in patients where CT scans are not sensitive enough
- Minimal Residual Disease monitoring. Regular profiling can quantify therapy response based on mutant allele frequency.

#### **METHOD:**

Next Generation Deep Sequencing. With minimal amounts of input DNA, profiling of multiple genes in a single assay including different tumor signatures like Single nucleotide variations (SNVs), Copy number variations (CNVs), Gene fusion events and Exon skipping event. The test utilizes cell free Total Nucleic Acid (cfTNA) content rather than just cfDNA with average sequencing coverage of 30000 - 40000X enable detection at extremely low allele frequencies

#### **TEST SENSITIVITY:**

Assay is validated inhouse using control and reference samples, with LOD down to 0.1% for SNVs


SAMPLE: 20 ml Blood in cfBCT (Streck/Paxgene) tubes. Doesn't require urgent shipping/cold-chain support. weeks

| Sensitivity | Specificity | LOD  |
|-------------|-------------|------|
| >99%        | 100%        | 1%   |
| >99%        | 100%        | 0.5% |
| ≥82%        | 100%        | 0.1% |



**BIOSERVE BIOTECHNOLOGIES (INDIA) PVT LTD** 

Pinnacle Towers, 1st Floor, Plot No.9/17/A&B Road No.6, IDA, Nacharam, Medchal-Malkagiri Dist. Hyderabad-500076, Telangana





+91 912 122 9283



salesindia@reprocell.com







